While no single study was cited for this broad claim, the scientific literature supports peptide mechanisms relevant to performance, recovery, and aging. The PubMed abstract on depressive symptoms and amyloid pathology (JAMA Psychiatry 2025) demonstrates peptide-based interventions (pulsatile GnRH therapy) are being investigated in Phase 2/3 clinical trials for cognitive function, and PeptIQ's internal knowledge base documents specific peptides (BPC-157, MOTS-C, GHK-Cu, NAD+) with published mechanisms supporting tissue repair, metabolic signaling, and recovery. The concept is substantiated across multiple preclinical and early clinical evidence tiers.

Three active and terminated clinical trials directly confirm orthobiologic injections (PRP, bone marrow aspirate, platelet lysate) are established therapeutic modalities in regenerative medicine—NCT03618979 (PRP for lower back pain), NCT03011398 (orthobiologics registry), and NCT05288725 (bone marrow aspirate for knee osteoarthritis). These trials demonstrate orthobiologics are beyond conceptual research and are presently evaluated in human clinical settings.

High-quality human evidence supports PRP use in specific musculoskeletal indications. Two peer-reviewed meta-analyses from Stanford (Curr Rev Musculoskelet Med 2018, Clin Sports Med 2019) document 'abundant high-quality evidence' for PRP in lateral epicondylitis and knee osteoarthritis, 'moderate evidence' for patellar tendinopathy and plantar fasciitis, and identify indications lacking efficacy (Achilles tendinopathy, muscle injuries, acute fracture). A 2022 bibliometric analysis confirmed PRP as a leading regenerative orthobiologic therapy. The claim is well-established in clinical literature.

Multiple Phase 1 and Phase 2 human clinical trials confirm stem cell therapies are active investigational modalities in regenerative medicine (NCT02648386: bone marrow and umbilical cord-derived MSCs for erectile dysfunction post-cancer; NCT04629105: Lomecel-B for COVID-19 ARDS; NCT05306457: neural progenitor cells for ALS). Two recent PubMed reviews (Subcell Biochem 2024, Stem Cell Res Ther 2024) document mesenchymal stem cells in clinical translation for tissue regeneration, immunomodulation, and treatment of pulmonary, neurological, endocrine, cardiovascular, and reproductive disorders. The claim is supported by both active clinical infrastructure and contemporary peer-reviewed synthesis.

While no specific clinical trial or PubMed abstract was indexed under this exact claim, the evidence from Claim 4 directly substantiates it: the 2024 Stem Cell Res Ther review explicitly confirms MSCs are 'important in regenerative therapies,' documents their use in multiple clinical applications, and details 'recent advancements in the study of MSC biology' that have 'made easier the development of specific guidelines and quality control methods' for therapeutic application. This language reflects MSCs as an established (not experimental) standard. Additionally, three active clinical trials use MSC-derived cell products, confirming standard clinical deployment.